OVERVIEW

Multiple Myeloma (MM): Updates from 23rd Annual Congress of EHA (EHA 2018) is organized by ScientiaCME.

Release Date: April 15, 2019
Expiration Date: April 15, 2021

Target Audience:
The following healthcare professionals: hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.

Accreditation:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of .75 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists:
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 0.75 hours (0.075 CEUs) of continuing education. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE # 0574-0000-19-011-H01-P. ACPE Accreditation effective 4/21/19, expires 4/21/21.

Program Description / Statement of Need:
In this online CME self-learning program:
Annual meetings of large, national, professional societies offer an opportunity for healthcare professionals to get a first glimpse at study results that have the potential to impact practice as provide a forum for an exchange of ideas and practices between thought leaders and less distinguished practitioners. EHA 2018 is no exception. Nevertheless, as with every meeting, many professionals from both the community and health-system settings alike will be unable to attend the conference for a variety of reasons, justifying the creation of educational programming that summarize the major findings presented at the meeting.

Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus. While MM only makes up about 1% of all cancers, it the most common of the blood cancers with an incidence of a little under 31,000 and an annual mortality rate of just under 13,000. The peak incidence age of MM is at about 70 years of age, and the disease occurs twice as commonly in African Americans as it does in whites.

Program Objectives:
By the end of the session the participant will be able to:
• Summarize the most impactful findings presented at EHA 2018 meeting relating to initial treatment of transplant eligible and ineligible myeloma
• Summarize the most impactful findings presented at EHA 2018 meeting relating to role of autologous stem cell transplant
• Summarize the most impactful findings presented at EHA 2018 meeting relating to current role of monoclonal antibodies
• Summarize the most impactful findings presented at EHA 2018 meeting relating to novel immune therapies